These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dose intensified molecular targeted radiotherapy for cancer-lymphoma as a paradigm. DeNardo G; DeNardo S Semin Nucl Med; 2010 Mar; 40(2):136-44. PubMed ID: 20113681 [TBL] [Abstract][Full Text] [Related]
3. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. Sharkey RM; Goldenberg DM J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660 [TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376 [TBL] [Abstract][Full Text] [Related]
5. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. Gregory SA; Hohloch K; Gisselbrecht C; Tobinai K; Dreyling M Oncologist; 2009; 14 Suppl 2():4-16. PubMed ID: 19819920 [TBL] [Abstract][Full Text] [Related]
6. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step. Otte A; van de Wiele C; Dierckx RA Nucl Med Commun; 2009 Jan; 30(1):5-15. PubMed ID: 19020470 [TBL] [Abstract][Full Text] [Related]
7. Development of 131I-tositumomab. Lewington V Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026 [TBL] [Abstract][Full Text] [Related]
8. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684 [TBL] [Abstract][Full Text] [Related]
9. Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. Postema EJ; Raemaekers JM; Oyen WJ; Boerman OC; Mandigers CM; Goldenberg DM; van Dongen GA; Corstens FH Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3995S-4002S. PubMed ID: 14506199 [TBL] [Abstract][Full Text] [Related]
10. Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. Multani P Int J Hematol; 2002 Dec; 76(5):401-10. PubMed ID: 12512834 [TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists. Macklis RM; Pohlman B Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):833-41. PubMed ID: 16965871 [TBL] [Abstract][Full Text] [Related]
16. Current status of cancer therapy with radiolabeled monoclonal antibody. Oriuchi N; Higuchi T; Hanaoka H; Iida Y; Endo K Ann Nucl Med; 2005 Jul; 19(5):355-65. PubMed ID: 16164191 [TBL] [Abstract][Full Text] [Related]
17. Rituximab and other emerging monoclonal antibody therapies for lymphoma. Tobinai K Expert Opin Emerg Drugs; 2002 Oct; 7(2):289-302. PubMed ID: 15989552 [TBL] [Abstract][Full Text] [Related]
18. Conventional treatments for non-Hodgkin's lymphoma: the need for new therapies. Moskowitz CH J Nucl Med; 1998 Aug; 39(8 Suppl):2S-10S. PubMed ID: 9708564 [TBL] [Abstract][Full Text] [Related]
19. [Radioimmunotherapy of follicular lymphoma: a step towards cure?]. Ketterer N; Bischof Delaloye A; Helg C; Luthi F; Buchegger F Bull Cancer; 2007 Sep; 94(9):799-806. PubMed ID: 17878100 [TBL] [Abstract][Full Text] [Related]